Tag: peptide receptor radionuclide therapy

10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

• PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society

DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…

3rd Theranostics World Congress Offers Free Patient Program on March 14

Johns Hopkins University in Baltimore, Maryland will be the site of the 3rd Theranostics World Congress on Ga-68 & PRRT from March 12-14, 2015. Co-sponsored by the Society of Nuclear Medicine and Molecular Imaging and Johns Hopkins Medicine, the…

Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging 2014 Meeting

Josh Mailman, President of the NorCal CarciNET Community  and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June…

New Jersey Carcinoid Cancer NETwork Conference in November, Registration through October 16

Three of the country’s leading carcinoid and neuroendocrine cancer specialists will be featured speakers for the New Jersey Carcinoid Cancer NETwork Conference. to be held on Saturday, November 2, 2013 at the Crowne Plaza in Edison, New Jersey.  Carcinoid/NETs: …

Excel Diagnostics and Nuclear Oncology Center Selected For New Investigational PRRT Treatment and Gallium Scan for Carcinoid and Neuroendocrine Tumor Patients

For carcinoid, pancreatic neuroendocrine tumor, and other NET cancer patients seeking the most advanced nuclear medicine opportunities in  the United States, Excel Diagnostics and Nuclear Oncology Center  in Houston, Texas, in collaboration with…

2nd World Congress on Ga-68, Molecular Imaging & Targeted Radionuclide Therapy

Chandigarh, India will be the site of the 2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceuticals), Molecular Imaging (PET/CT), Targeted Radionuclide Therapy and Dosimetry:  On the Way to Personalized Medicine from February 28 through…

FDA Approves Amendment for PRRT Clinical Trial in Texas

BREAKING NEWS:  The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…

Pancreatic Neuroendocrine Tumors: A Rare Cancer

From your next door neighbor to Steve Jobs, co-founder of Apple who just announced that he is stepping down as CEO of the company, pancreatic neuroendocrine tumors (pNETs) affect less than 1 person in 100,000 in the United States.  This rare cancer is often…

Breaking News: Pancreatic NET Cancer Patient Steve Jobs Steps Down as CEO of Apple

On August 24, 2011, Steve Jobs, CEO of Apple, announced that he was stepping down from his position.  In his letter to the Apple Board of Directors and the Apple Community, Mr. Jobs wrote, “I have always said if there ever came a day when I could no longer meet…